The concern of generic rivalry has consistently loomed above copyright’s blockbuster drug, Sildenafil, sparking questions about the prospects of similar medicinal stakes. While initial years saw substantial returns, the patent end has allowed the path for discounted alternatives, potentially lowering revenue and posing a real risk for investors s